Teva Pharmaceuticals USA Inc.'s suit against the US FDA aims to obtain 180-day exclusivity for its generic version of Allergan PLC's Restasis (cyclosporine) and to eliminate the agency's new policy redefining "first applicant."
Teva's complaint is in response to a letter FDA issued in July to applicants of abbreviated new drug applications for generic versions of Indivior PLC's Suboxone (buprenorphine/naloxone) sublingual film. In the letter, the agency set forth a new definition of "first applicant," whereby a sponsor does not lose this status by failing to provide timely notice of Paragraph IV certification to the brand manufacturer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?